LOR 2040

Drug Profile

LOR 2040

Alternative Names: GTI-2040; LOR-2040

Latest Information Update: 04 Sep 2015

Price : $50

At a glance

  • Originator Lorus Therapeutics
  • Developer Aptose Biosciences
  • Class Antineoplastics; Oligodeoxyribonucleotides
  • Mechanism of Action DNA synthesis inhibitors; Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Renal cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Bladder cancer; Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 04 Sep 2015 No recent reports on development identified - Phase-II for Renal cancer (Combination therapy, Metastatic disease) in USA (IV)
  • 04 Sep 2015 No recent reports on development identified - Phase-II for Prostate cancer (Combination therapy, Hormone refractory) in Canada (IV)
  • 04 Sep 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease) in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top